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i 
x HAS BEEN s n o w y  by Sun 1 that  the adminis t ra t ion  of  g lycopyrrola te  
(Robinul )  to pat ients  with duodena l  ulcer results in a lowered incidence 
of  symptomat ic  recurrences. Since there is a lack of cont ro l led  studies evalu- 
a t ing  the effectiveness of  therapeut ic  regimens on  the long-term course of 
duodena l  ulcer, it was decided to repeat  the studies of Sun. 
M E T H O D S  
T h e  records of  pat ients  admi t t ed  to the Veterans Admin i s t r a t ion  Hospi ta l  
of A n n  A r b o r  for the years 1953 to 1964 and  diagnosed as suffering f rom duo- 
denal  ulcer were examined.  Patients who had  definitive opera t ions  for the 
relief of  ulcer were excluded.  T h e  r emainder  were sent a letter ou t l in ing  the 
objective of  the s tudy and  were invited to par t ic ipa te  p rov ided  they had  
suffered f rom significant ulcer symptoms du r ing  the previous year. Pat ients  
who  responded  were admi t ted  to the Veterans Admin i s t r a t ion  Hospi ta l  for  a 
per iod of  5 days. D u r i n g  this per iod their  clinical status was evaluated,  and  
the dura t ion  and  intensi ty of ulcer S~Tnptoms du r ing  the recent  past  was 
ascertained. A n  u p p e r  gastrointest inal  tract X-ray examina t ion  was performed.  
I f  the patients '  symptoms were compat ib le  wi th  duodena l  ulcer and  if, in 
addi t ion,  they showed significant duodena l  bu lb  deformity,  a duodena l  ulcer 
crater, or  both,  they were admi t ted  to the study. Pat ients  were then placed on  
the s tudy protocol  and du r ing  their stay in the hospi ta l  received glycopyrrola te  
in increasing doses to a m a x i m u m  of 2 mg. 3 times per  day or  unti l  tolerance 
was reached. I n  general  this requi red  2 tablets (1 mg. per  tablet) 3 times a 
day. Care was taken to ascertain tha t  in the doses used, side effects were present  
bu t  minimal .  U p o n  discharge f rom the hospi ta l  each pa t ien t  was given a 
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study number, and a supply of tablets identified by the study nmnber  was 
set aside in the pharnlacy of the hospital. These tablets either contained glyco- 
pyrrolate in (loses of 1 rng. per tablet or a placebo, (a mixture of calcium 
phosphate, carbowax, starch, lactose, and magnesium stearate). In addition 
each tablet contained 2.5 rag. of riboflavin, an amount  sufficient to impart  a 
deep yellow color to the urine particularly evident when examined with an 
ultraviolet lamp. A similar procedure has recently been described by Jones.'-' 
Assignment to drug and placebo groups was on a double-blind basis. T h e  
code was kept sealed in the pharmacy of the hospital. (To conform with 
interstate shipping requirements, each bottle was doubly labeled, the outer 
label identified the drug, the inner label indicated the study number  of the 
patient. Upon  the arrival of the shipment the outer  label was removed by the 
secretarial staff in the absence of any of the investigators). 
After discharge from the hospital patients were seen at intervals of 6 weeks. 
On each visit a routine symptomatic inquiry and physical examination were 
carried out. T h e  incidence of gastrointestinal symptoms, their duration, and 
intensity were noted. Absence from work at tr ibuted to ulcer disease was docu- 
mented. Th e  impression of both the examiner  and the patient regarding the 
effectiveness of treatment was recorded. T h e  urine was examined to determine 
whether the patient was taking the drug. T h e  need for antacids was ascertained. 
Patients were discouraged from taking anticholinergic medications other than 
those which may have been contained in the tablets provided. All patients 
were instructed to cease taking possible ulcerogenic drugs such as salicylates, 
and to avoid the use of tobacco and alcohol. They  were further  encouraged 
to pursue a 6-feeding program. These instructions were reiterated on each visit. 
Each patient  was followed in this manner  for 18-27 months. When all 
patients had been discharged, the response to treatment over the entire period 
was assessed independently by two of us (J.A. and K.S.H.). According to this 
evaluation the patients who had been followed throughout  the period of 
observation were assigned to 1 of 3 groups: " improvement ,"  "no change," or 
"worse." Th e  over-all impression was based on symptoms, complications, loss of 
working time, and the evaluation of patient and examiner as recorded on each 
visit. This  was then compared with the patterns of the patient  prior  to entering 
the trial. Both observers agreed independently on all but  2 of the patients. 
(One patient eventually placed in the " improved" group received the drug, 
and 1 patient  eventually placed in the "no change" group received placebo.) 
All patients who received surgical correction of their duodenal ulcer during 
the period of study were assigned to the "worse" category. After each patient 
had been finally assigned, the code was broken and the results evaluated. 
RESULTS 
A total of 151 patients were considered. After examinat ion in the hospital 
59 entered the study. The  majority of the 92 patients thus excluded failed to 
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answer  tile i n i t i a l  i nv i t a t i on ;  a few were f o u n d  no t  to have s ignif icant  u lcer  
symptoms  o r  d e m o n s t r a b l e  ulcer  disease. T h i r t e e n  pa t i en t s  fa i led  to a t t e n d  
for fo l low-up (5 received the drug ,  the r e m a i n d e r  the  p l a c e b o ) .  T h e  r e m a i n i n g  
46 could  be eva lua ted .  Al l  those who r e m a i n e d  in  the s tudy took the  medica -  
t ion,  as shown by u r i n a r y  fluorescence. 
T h e  resul ts  are s u m m a r i z e d  in  T a b l e  1. T h e r e  was no  s ignif icant  d i f ference  
a t t r i b u t a b l e  to the drug .  T o  exc lude  the poss ib i l i ty  tha t  chance  differences in  
age, d u r a t i o n  of symptoms,  inc idence  of compl ica t ions ,  or  associa ted diseases 
(d iabe tes  mel l i tus ,  ch ron ic  b ronchi t i s ,  a r t e r iosc le ro t i c  h e a r t  diseases) m a y  have  
in f luenced  the results ,  these facts were r e c o r d e d  separa te ly .  T h e s e  d a t a  are  
s u m m a r i z e d  in  T a b l e  2. T h e  m e a n  age was v i r t u a l l y  the  same in a l l  3 groups ,  
a n d  c o m p a r a b l e  in its d i s t r i b u t i o n  be tween  the " i m p r o v e d "  a n d  "worse"  
groups .  A l t h o u g h  the di f ference was no t  s ta t i s t ica l ly  s ignif icant ,  the  d u r a t i o n  
of  symptoms  in those who  were i m p r o v e d  a n d  rece ived  the  d r u g  was longe r  
c o m p a r e d  wi th  those who  i m p r o v e d  a n d  rece ived  the  p lacebo .  As o u r  resul ts  
were  d i f fe ren t  f rom those r e p o r t e d  previous ly ,  the  d a t a  f rom o u r  pa t i en t s  
were  c o m p a r e d  w i th  those r e p o r t e d  by Sun. 1 B o t h  series desc r ibed  a p o p u l a t i o n  
of males  us ing  the  faci l i t ies  of a Vete rans  A d m i n i s t r a t i o n  Hosp i t a l ,  a n d  there-  
fore a re  no t  necessar i ly  r ep re sen t a t i ve  of  the  d u o d e n a l  u lcer  p o p u l a t i o n  as a 
TABLE 1. RESPONSE TO GLYCOPYRROLATE 
Drug Placebo Total 
hnproved 14 11 25 
Worse 8 8 16 
No change 4 1 5 
TOTAL 26 20 46 
Chi-" was 0.05; p > 0.90. 
TABLE 2. RESPONSE RELATED TO AGE, DURATION OF SYMPTOMS, 
COMPLICATIONS, AND ASSOCIATED DISEASES 
Duration of Complications 
Age symptoms due to Associated Total No, 
(yr.) (yr.) ulcer diseases or pa'i nts 
I M PROVED 
Drug 49.3---11.2 16.2 -+ 8.8 5 6 14 
Placebo 53.7± 12,5 13.4± 8.5 6 6 11 
WORSE 
Drug 55.7±13.3 13.6-+ 8.9 3 7 8 
Placebo 5t.3 -+ 11.2 16.2 -+ 8.1 3 5 8 
NO CHANGE 
Drug 57.2 -+ 17.11 23.0 --+ 17.1 3 1 4 
Placebo 31 7 1 0 I 
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TABLE 3. COMPARISON OF PRESENT AND EARLIER STUDIES (ALL PATIENTS) 
Complications due to ulcer 
Duration of before entering study 
symptoms 
Age (years) (years) No,/total % 
Sun 38,6± 9.3 9.2± 5.9 32/37 87 
Fhis series 52,1 ± 14.6 15.2 ±- 10.9 26/46 57 
p < 0.001 p < 0.00I p < 0.0I 
who e. The  age distribution, durat ion of the disease, and tile incidence of 
complications prior to treatment in the series reported by Sun and in our  
study is shown in Table  3. The  patients studied by Sun were significantly 
younger and their symptoms had been present for a shorter period of time. 
On the other hand, the incidence of complications prior to the start of therapy 
was higher in Sun's series (86%) compared with ours (57~o). In our  series 
one comp!ication occurred in the course of therapy (hemorrhage in one of 
the patients receiving the placebo).  Serious complications occurred in 10 of 17 
patients receiving the placebo in the patients described by Sun compared with 
only 1 of 20 receiving the drug. T h e  patients studied by us were therefore 
older, had their disease for a longer period of time, and were less prone to 
complications. 
DISGUSSION 
There  is a recognized need for an effective therapeutic regimen which 
prevents recurrence of symptoms and disability in patients with known duo- 
denal ulcer who have been treated successfully during the initial episode 
which ted to diagnosis. T h e  observations of Sun 1 have suggested that glyco- 
pyrrolate may be of significant benefit in meeting this need. Our observations 
have not confirmed this, and the reasons for this difference in results are 
not clear. 
Both series employed different means of ensuring that the patients were 
receiving their medications. Our patients were unlikely to recognize the 
objective of the examination of the urine. On the other hand, our  method of 
assessment only indicated that the drug had been taken immediately before 
the outpat ient  visit. T h e  method employed by Sun (i.e., counting of the 
remaining tablets at each visit) is obviously capable of manipulat ion by the 
patient and the purpose of this method of assessment is more easily recognized. 
Neither procedure, therefore, is entirely free from possible error, but  both series 
agree that virtually all the patients consumed the medication provided. 
In both series the durat ion of symptoms in those who received the drug was 
slightly longer than those who received the placebo, al though in neither 
instance was this statistically significant. This  argues against the hypothesis 
that failure to respond to the drug might have been due to chronicity as 
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implied by longer dura t ion  of symptoms. I t  therefore became impor tan t  to 
determine whether  the 2 series were comparable  in other respects. The re  were 
significant differences in the 2 series in age, durat ion of symptoms, and inci- 
dence of complications. In  this series we repor t  patients who were older, whose 
disease had been present for a longer period of time, and who were less prone 
to develop complications either before or dur ing the course of observation. 
As both  series were selected from patients who had not been treated surgically, 
this may reflect differences in policy between the 2 hospitals. I t  is likely that 
many  of the patients studied by Stm would have been treated surgically in 
this institution. Furthermore,  our hospital serves a large and, at least in part,  
rural  area of Michigan, and many patients are living at some distance f rom 
the hospital. T h e  Moun t  Alto Veterans Adminis t ra t ion Hospital  is located 
in the center of a large urban  area and presumably serves such a populat ion.  
This  suggests the selectiveness inherent  in any sample reported f rom one 
institution. I t  is therefore possible that yotmger patients whose ulcers are less 
chronic and who are liable to acute exacerbations while still main ta in ing  the 
ability to heal their  ulcers, are more likely to respond to glycopyrrolate or  
similar drugs as compared  with older groups of patients with more chronic 
ulcers less likely to suffer f rom acute exacerbations and less likely to heal. 
In  this series a small n u m b e r  of patients showing "no change" have been 
separated f rom those who were regarded as improved and those in whom treat- 
ment  was considered to have failed. This  represents a category not  repor ted 
by Sun. T h e  classification became necessary because in 5 patients the pat tern  
of symptoms had not  changed while under  observation. The re  is little 
justification for including such patients in the "failure" group because ad- 
ministrat ion of the drug may have prevented the natural  progression of the 
disease. On the other  hand,  as these patients  were not improved they could 
not  reasonably be regarded as having benefited by the treatment.  
SUMMARY 
A double-blind controlled study of the effect of glycopyrrolate on 46 patients  
with duodenal  ulcer is reported. 
No beneficial effect of the drug over a period of 18-27 months  could be 
demonstrated.  Possible reasons for the difference between this study and that  
reported previously are discussed. 
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